Insight Pharmaceuticals Corp

Businessfiled

Insight Pharmaceuticals Corp operates in Other, based in LANGHORNE.

Sector still resolves to a broad 'Other' bucket, so operating comparables below are weaker than for a tightly-classified peer.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Insight Pharmaceuticals Corp has raised $103M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).

Largest single filing: $65M on 2011-08-12.

Most recent recorded round closed around 2011-08-12.

Valuation (modeled)modeled

Provath models Insight Pharmaceuticals Corp at approximately $1.1B (range $251M–$2.9B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.23× the median modeled value of Series C Other companies in 2010–2012 (152 peers) — value vs value, same stage and era. Within the normal band (123% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 13 months.

Last raise 14.9 yr ago; this sector typically re-raises about every 11 months.

Silent for over 3× the sector's normal cadence.

The last round stepped up 11.6× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 96% of Other peers (25015 compared).

Modeled value ranks above 97% of those peers.

Closest niche peers: China XD Plastics Co Ltd, TPG-Axon Cube Trust, TPG-Axon Cube Sa rl, Ralco Holdings, Inc., 1-800-Pack-Rat, LLC.

Peoplefiled

16 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

Broad sector classification weakens peer comparison.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.